Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019

Husam Ahmed, Steve Turner (Corresponding Author)

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Severe asthma is a relatively uncommon condition in children but one which causes morbidity, occasionally mortality, and is a challenging condition to manage. There are several definitions of severe asthma, which have a common theme of poor control despite high dose inhaled corticosteroid treatment. Depending on the definition chosen, the prevalence of severe childhood asthma may be up to 5% within populations with asthma. Collectively, there is some evidence that the treatments used in severe asthma are beneficial, but a solid evidence‐base is lacking for many treatments and some treatments have recognized side effects. Evidence supporting the use of maintenance oral prednisolone and intramuscular triamcinolone is weak. Response to systemic corticosteroids is heterogeneous and recognizing phenotypes or endotypes may identify those most likely to gain maximal benefit from treatment. For children aged 6 to 11 years, the anti‐IgE biologic omalizumab is effective and anti‐IL‐5 agent (mepolizumab) has recently been licenced in Europe (but not the US). Biologics, which are licenced for >11 year olds include omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab. There is plenty that the clinician can offer to the child and adolescent with severe asthma in 2019, including nontherapeutic and therapeutic interventions. To manage severe asthma, practitioners from broad specialities must establish and maintain a close therapeutic relationship with patients. Looking beyond 2019, more treatment options will emerge for severe childhood asthma, and clinical teams will need to continue weighing up benefits and harms.
Original languageEnglish
Pages (from-to)778-787
Number of pages10
JournalPediatric Pulmonology
Volume54
Issue number6
Early online date18 Mar 2019
DOIs
Publication statusPublished - 1 Jun 2019

Fingerprint

Epidemiology
Asthma
Therapeutics
Adrenal Cortex Hormones
Triamcinolone
Prednisolone
Biological Products
Maintenance
Morbidity
Phenotype
Mortality
Population

Keywords

  • asthma
  • biologics
  • child
  • corticosteroids
  • randomized controlled trial
  • OMALIZUMAB
  • ESOMEPRAZOLE
  • PROBLEMATIC SEVERE ASTHMA
  • MANAGEMENT
  • MEPOLIZUMAB
  • CHILDHOOD
  • ADHERENCE
  • RESISTANT ASTHMA
  • TRIAMCINOLONE
  • CORTICOSTEROIDS

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019. / Ahmed, Husam; Turner, Steve (Corresponding Author).

In: Pediatric Pulmonology, Vol. 54, No. 6, 01.06.2019, p. 778-787.

Research output: Contribution to journalArticle

@article{737a14a47b804df3b3c2ac5283108bc5,
title = "Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019",
abstract = "Severe asthma is a relatively uncommon condition in children but one which causes morbidity, occasionally mortality, and is a challenging condition to manage. There are several definitions of severe asthma, which have a common theme of poor control despite high dose inhaled corticosteroid treatment. Depending on the definition chosen, the prevalence of severe childhood asthma may be up to 5{\%} within populations with asthma. Collectively, there is some evidence that the treatments used in severe asthma are beneficial, but a solid evidence‐base is lacking for many treatments and some treatments have recognized side effects. Evidence supporting the use of maintenance oral prednisolone and intramuscular triamcinolone is weak. Response to systemic corticosteroids is heterogeneous and recognizing phenotypes or endotypes may identify those most likely to gain maximal benefit from treatment. For children aged 6 to 11 years, the anti‐IgE biologic omalizumab is effective and anti‐IL‐5 agent (mepolizumab) has recently been licenced in Europe (but not the US). Biologics, which are licenced for >11 year olds include omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab. There is plenty that the clinician can offer to the child and adolescent with severe asthma in 2019, including nontherapeutic and therapeutic interventions. To manage severe asthma, practitioners from broad specialities must establish and maintain a close therapeutic relationship with patients. Looking beyond 2019, more treatment options will emerge for severe childhood asthma, and clinical teams will need to continue weighing up benefits and harms.",
keywords = "asthma, biologics, child, corticosteroids, randomized controlled trial, OMALIZUMAB, ESOMEPRAZOLE, PROBLEMATIC SEVERE ASTHMA, MANAGEMENT, MEPOLIZUMAB, CHILDHOOD, ADHERENCE, RESISTANT ASTHMA, TRIAMCINOLONE, CORTICOSTEROIDS",
author = "Husam Ahmed and Steve Turner",
year = "2019",
month = "6",
day = "1",
doi = "10.1002/ppul.24317",
language = "English",
volume = "54",
pages = "778--787",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "John Wiley & Sons, Ltd",
number = "6",

}

TY - JOUR

T1 - Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019

AU - Ahmed, Husam

AU - Turner, Steve

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Severe asthma is a relatively uncommon condition in children but one which causes morbidity, occasionally mortality, and is a challenging condition to manage. There are several definitions of severe asthma, which have a common theme of poor control despite high dose inhaled corticosteroid treatment. Depending on the definition chosen, the prevalence of severe childhood asthma may be up to 5% within populations with asthma. Collectively, there is some evidence that the treatments used in severe asthma are beneficial, but a solid evidence‐base is lacking for many treatments and some treatments have recognized side effects. Evidence supporting the use of maintenance oral prednisolone and intramuscular triamcinolone is weak. Response to systemic corticosteroids is heterogeneous and recognizing phenotypes or endotypes may identify those most likely to gain maximal benefit from treatment. For children aged 6 to 11 years, the anti‐IgE biologic omalizumab is effective and anti‐IL‐5 agent (mepolizumab) has recently been licenced in Europe (but not the US). Biologics, which are licenced for >11 year olds include omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab. There is plenty that the clinician can offer to the child and adolescent with severe asthma in 2019, including nontherapeutic and therapeutic interventions. To manage severe asthma, practitioners from broad specialities must establish and maintain a close therapeutic relationship with patients. Looking beyond 2019, more treatment options will emerge for severe childhood asthma, and clinical teams will need to continue weighing up benefits and harms.

AB - Severe asthma is a relatively uncommon condition in children but one which causes morbidity, occasionally mortality, and is a challenging condition to manage. There are several definitions of severe asthma, which have a common theme of poor control despite high dose inhaled corticosteroid treatment. Depending on the definition chosen, the prevalence of severe childhood asthma may be up to 5% within populations with asthma. Collectively, there is some evidence that the treatments used in severe asthma are beneficial, but a solid evidence‐base is lacking for many treatments and some treatments have recognized side effects. Evidence supporting the use of maintenance oral prednisolone and intramuscular triamcinolone is weak. Response to systemic corticosteroids is heterogeneous and recognizing phenotypes or endotypes may identify those most likely to gain maximal benefit from treatment. For children aged 6 to 11 years, the anti‐IgE biologic omalizumab is effective and anti‐IL‐5 agent (mepolizumab) has recently been licenced in Europe (but not the US). Biologics, which are licenced for >11 year olds include omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab. There is plenty that the clinician can offer to the child and adolescent with severe asthma in 2019, including nontherapeutic and therapeutic interventions. To manage severe asthma, practitioners from broad specialities must establish and maintain a close therapeutic relationship with patients. Looking beyond 2019, more treatment options will emerge for severe childhood asthma, and clinical teams will need to continue weighing up benefits and harms.

KW - asthma

KW - biologics

KW - child

KW - corticosteroids

KW - randomized controlled trial

KW - OMALIZUMAB

KW - ESOMEPRAZOLE

KW - PROBLEMATIC SEVERE ASTHMA

KW - MANAGEMENT

KW - MEPOLIZUMAB

KW - CHILDHOOD

KW - ADHERENCE

KW - RESISTANT ASTHMA

KW - TRIAMCINOLONE

KW - CORTICOSTEROIDS

UR - https://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.24317

UR - http://www.mendeley.com/research/severe-asthma-childrena-review-definitions-epidemiology-treatment-options-2019

UR - http://www.scopus.com/inward/record.url?scp=85066918672&partnerID=8YFLogxK

U2 - 10.1002/ppul.24317

DO - 10.1002/ppul.24317

M3 - Article

VL - 54

SP - 778

EP - 787

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 6

ER -